• 1
    Latthe P, Mignini L, Gray R, Khan KS. Factors predisposing women to chronic pelvic pain: a systematic review. BMJ 2006;332:74955.
  • 2
    Howard FM. The role of laparoscopy in chronic pelvic pain: promise and pitfalls. Obstet Gynecol Surv 1993;48:35787.
  • 3
    Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life and economic correlates. Obstet Gynecol 1996;87:3217.
  • 4
    Davies L, Ganger K, Drummond M, Saunnders D, Beard R. The economic burden of intractable gynaecological pain. J Obstet Gynaecol 1992;12:4654.
  • 5
    The Initial Management of Chronic pelvic pain. RCOG Green top guideline No. 41, April 2005.
  • 6
    Zondervan KT, Yudkin P, Vessey MP, Jenkinson CP, Dawes MG, Barlow DH, et al. Chronic pelvic pain in the community—symptoms, investigations and diagnoses. Am J Obstet Gynecol 2001;184:114955.
  • 7
    Malykhina AP. Neural mechanisms of pelvic organ cross-sensitization. Neuroscience 2007;149:66072.
  • 8
    Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001;429:17793.
  • 9
    Borgbjerg FM. Visceral Pain and its Management. Copenhagen, Denmark: The Pain clinic, Bispebjerg Hospital, University of Copenhagen; 1996.
  • 10
    Moshiree B, Zhou Q, Price D, Verne GN. Central sensitisation in visceral pain disorders. Gut 2006;55:9058.
  • 11
    Bueno L, Fioramonti J, Garcia-Villar R. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol Gastrointest Liver Physiol 2000;278:G6706.
  • 12
    Mayer E, Gebhart G. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994;107:27193.
  • 13
    Zhizhong ZP. An intensified descending pain-facilitating pathway. Drug Discov Today: Dis Models 2004;1 2:1215.
  • 14
    Bingel U. Tracey I.Imaging CNS modulation of pain in humans. Physiology 2008;23:37180.
  • 15
    Mayer EA. Commentary on peripheral and central contributions to hyperalgesia in irritable bowel syndrome. The Journal of Pain 2006;7:53941.
  • 16
    Al-Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000;119:127685.
  • 17
    Gregory LJ, Aziz Q. Understanding Functional Gastrointestinal Disorders and Functional Brain Imaging Techniques. Business Briefing: Global health care. 2002.
  • 18
    Stones W. Medical management of chronic pelvic pain. Obst Gynaecol Reprod Med 2008;18:2335.
  • 19
    Ojha K, Matah A. Surgical management of chronic pelvic pain. Obstet Gynaecol Reprod Medi 2008;18.
  • 20
    Junien JL, Riviere P. Review article: the hypersensitive gut-peripheral kappa agonists as a new pharmacological approach. Aliment Pharmacol Ther 1995;9:1179.
  • 21
    Micó J, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends Pharmacol Sci 2006;27:34854.
  • 22
    Serpell M. Anatomy, physiology and pharmacology of pain. Surgery 2006;24:10, 3503.
  • 23
    Bueno L, De Ponti F, Fried M, Kullak-Ublick GA, Kwiatek MA, Pohl D. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol Motil 2007;19 (Suppl 1):89119.
  • 24
    Engel CC, Walker EA, Engel AL, Bullis J, Armstrong A. A randomised, double-blind crossover trial of sertraline in women with chronic pelvic pain. J Psychosom Res 1998;44:2037.
  • 25
    Brown DG, Krupp J. N-Methyl-d-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr Top Med Chem 2006;6:74970.